REAL‐WORLD OUTCOMES OF PATIENTS (PT) WITH RELAPSED OR REFRACTORY (R/R) CLL/SLL AND PRIOR TREATMENT (TX) WITH BOTH A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND VENETOCLAX.
| Publicado en: | Hematological Oncology Vol. 41; pp. 733 - 735 |
|---|---|
| Autores principales: | , , , , |
| Formato: | Journal Article |
| Publicado: |
Wiley-Blackwell
Jun2023 Supplement S2
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=164231427&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 164231427 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 02780232 O85 jtl: Hematological Oncology issn: 02780232 maglogo: Y pubinfo: dt: Jun2023 Supplement S2 vid: 41 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 164231427 10.1002/hon.3165_586 164231427 ppf: 733 ppct: 2 formats: tig: atl: REAL‐WORLD OUTCOMES OF PATIENTS (PT) WITH RELAPSED OR REFRACTORY (R/R) CLL/SLL AND PRIOR TREATMENT (TX) WITH BOTH A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND VENETOCLAX. aug: au: Soumerai, J. Wang, L. Gu, F. Gu, T. Liu, F. F. affil: Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, USA sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|